Join to View Full Profile
1611 NW 12th Ave# M851Miami, FL 33136
Phone+1 305-243-1000
Fax+1 305-243-9927
Dr. Rosenblatt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1981 - 1983
- UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1980 - 1981
David Geffen School of Medicine at UCLAClass of 1980
Certifications & Licensure
CA State Medical License 1981 - Present
FL State Medical License 2003 - 2028
NY State Medical License 1995 - 2005
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
Clinical Trials
- Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma Start of enrollment: 1997 Nov 01
- Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors Start of enrollment: 1999 Apr 01
Publications & Presentations
PubMed
- 1 citationsFive-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, Narendranath Epperla, Matthew L Ulrickson
Journal of Clinical Oncology. 2025-11-20 - 1 citationsHigh rate of complete responses induced by platinum-based regimen with BTK inhibitors in Richter syndrome.Georgios Pongas, Maryam Alasfour, Daniel P Cassidy, Juan P Alderuccio, Joseph D Rosenblatt
Blood Advances. 2025-07-22 - 15 citationsLoncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial.Juan Pablo Alderuccio, Alvaro J Alencar, Jonathan H Schatz, Russ A Kuker, Georgios Pongas
The Lancet. Haematology. 2025-01-01
Press Mentions
Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition – Tip SheetNovember 13th, 2024- Sylvester Fuels Junior Faculty Members’ Research Careers with American Cancer Society GrantsMay 18th, 2023
Synergys Awarded NCI Grant to Develop SYN001 for Triple-Negative Breast CancerOctober 9th, 2017
Grant Support
- Host Defense Regulation By HTLV-1National Cancer Institute2009–2011
- Augmentation Of Anti-Tumor Activity In The Absence Of B CellsNational Cancer Institute2007–2011
- HSV Amplicon Activation Of Innate And Adaptive ImmunityNational Cancer Institute2004–2008
- Antibody Fusion Proteins For The Therapy Of CancerNational Cancer Institute2002
- Chemokine Enhanced Immune Therapy Of LymphomaNational Cancer Institute2001–2002
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
